Bristol-Myers Squibb Co (BMY)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$49.99

Buy

$50.11

arrow-up$0.17 (+0.34%)

Prices updated at 26 Sep 2024, 23:06 EDT

Prices minimum 15 mins delay

Prices in USD

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

S&P 500

0.4%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2022	2023
	46,159m	45,006m
	36,022m	34,313m
	9,104m	8,195m
	19.72	18.21
	6,327m	8,025m
	19,221m	19,366m
Sales, General and administrative	7,814m	7,772m
Interest expenses	1,232m	1,166m
Provision for income taxes	1,368m	400m
Operating expenses	26,918m	26,118m
Income before taxes	7,713m	8,440m
Net income available to common shareholders	6,327m	8,025m
	2.97	3.88
Net interest income	-1,232m	-1,166m
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	2.95	3.86
Free cash flow per share	5.862	5.5655
Book value/share	15.7451	14.3483
Debt equity ratio	1.169215	1.297418

Balance sheet

Year chevron-l-regular chevron-r-regular	2022	2023
Current assets	27,273m	31,770m
Current liabilities	21,890m	22,262m
Total capital	66,117m	66,083m
Total debt	40,717m	41,464m
Total equity	31,061m	29,430m
Total non current liabilities	-	-
Loans	35,056m	36,653m
Total assets	96,820m	95,159m
Total liabilities	-	-
Cash and cash equivalents	9,123m	11,464m
Common stock	2,075m	2,021m

Cash flow

Year chevron-l-regular chevron-r-regular	2022	2023
Cash at beginning of period	14,316m	9,325m
Cash dividends paid	-4,634m	-4,744m
	11,948m	12,651m
Investments (gains) losses	-1,062m	-2,295m
	9,325m	11,519m
Net income	-	-
	13,066m	13,860m
	-1,118m	-1,209m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.